RxDoctor Payments Data

Joseph Lattanzi, MD

Radiation Oncology · Manahawkin, NJNPI 1538145123

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Gilead at 29.5% of the total. Reporting peaked in 2023 at $170 and has fallen 89.8% since, to $17 in 2025. That places this record below the midpoint for radiation oncology clinicians in NJ, where the typical reported total is $491.

$331in general payments, 2019–2025

Across 7 payments — averaging $47.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$98
  • GSK$97
  • Stryker$72
  • Regeneron Healthcare Solutions, Inc.$21
  • Novartis$17
  • Sanofi$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$331100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$331 in reported general payments places this provider in the 40th percentile of 132 radiation oncology providers in New Jersey.

See all radiation oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$454,695
Medicare patients
338
Services billed
3,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Manahawkin

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →